Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy
There was no significant difference in OS or PFS between IO-IO and IO-TKI combination therapy as first-line treatment for patients with nccRCC. Liver metastasis is a poor prognostic factor for such patients.
Authors
- Kiyoshi Takahara (ORCID: https://orcid.org/0000-0002-4766-2074)
- Yosuke Hirasawa (ORCID: https://orcid.org/0000-0002-1563-4888)
- Takuya Tsujino (ORCID: https://orcid.org/0000-0003-1559-1889)
- Tatsushi Kawada (ORCID: https://orcid.org/0000-0002-8369-9712)
- Ryoichi Maenosono (ORCID: https://orcid.org/0000-0002-9045-5484)
- Wataru Fukuokaya (ORCID: https://orcid.org/0000-0003-1044-912X)
- Satoshi Katayama (ORCID: https://orcid.org/0000-0002-8377-2457)
- Haruhito Azuma (ORCID: https://orcid.org/0000-0001-5497-1679)
- Motoo Araki
- Takuhisa Nukaya (ORCID: https://orcid.org/0009-0007-9902-1694)
- Takafumi Yanagisawa (ORCID: https://orcid.org/0000-0002-7410-0712)
- Takahiro Adachi
- Shingo Toyoda (ORCID: https://orcid.org/0009-0008-2572-5071)
- Masanobu Saruta (ORCID: https://orcid.org/0009-0005-0774-1105)
- Yoshio Ohno (ORCID: https://orcid.org/0000-0001-5060-3932)
- Takeshi Hashimoto (ORCID: https://orcid.org/0000-0002-1157-4101)
- Kazumasa Komura (ORCID: https://orcid.org/0000-0003-4157-1929)
- Kazutoshi Fujita (ORCID: https://orcid.org/0000-0002-6774-7497)
- Ryoichi Shiroki (ORCID: https://orcid.org/0000-0002-4698-5947)
- Shingo Nishimura
- Takahiro Kimura
- Keiichiro Mori
Institutions
- Jikei University School of Medicine (JP)
- Tokyo Medical University (JP)
- Okayama University (JP)
- Okayama Prefecture (JP)
- Fujita Health University Hospital (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1093/jjco/hyae108
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26